Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, generates frequent news across human health, animal health and corporate finance. As a research-intensive biopharmaceutical company with more than a century of history developing medicines and vaccines, Merck regularly announces clinical trial milestones, regulatory decisions, business development transactions and capital markets activity.
Recent news highlights include oncology updates from Merck’s extensive KEYTRUDA program, such as positive Phase 3 data in muscle-invasive bladder cancer and new trials in non-small cell lung cancer using combinations like calderasib (MK-1084) with KEYTRUDA QLEX. The company also reports on progress in other therapeutic areas, including pulmonary arterial hypertension with WINREVAIR, Alzheimer’s disease candidates MK-2214 and MK-1167, and cardiovascular research with the oral PCSK9 inhibitor candidate enlicitide.
Investors following MRK news will also see announcements related to Merck Animal Health, such as the conditional U.S. FDA approval of EXZOLT CATTLE-CA1 for the prevention and treatment of New World screwworm larvae and the treatment and control of cattle fever tick, as well as updates on acquisitions like the planned merger with Cidara Therapeutics to add the influenza candidate CD388 to Merck’s respiratory portfolio.
Corporate and financial communications include quarterly earnings calls, participation in major healthcare conferences and disclosures about note offerings under the company’s shelf registration statement. This news page aggregates these developments so readers can review clinical, regulatory, strategic and financial updates related to Merck & Co., Inc. and its MRK stock in one place.
Merck (NYSE: MRK) presented late-breaking Phase 3 data for investigational doravirine/islatravir (DOR/ISL) as a once-daily, two-drug, non-INSTI regimen for adults with HIV-1.
In treatment-naïve adults DOR/ISL met non-inferiority at Week 48 (91.8% vs 90.6%; difference 1.2%, 95% CI -3.7, 6.2) and maintained viral suppression at Week 96 in switch studies. The U.S. FDA PDUFA target action date for the NDA is April 28, 2026.
Merck (NYSE: MRK) will participate in the TD Cowen 46th Annual Health Care Conference on Mar. 3, 2026. Caroline Litchfield, executive vice president and CFO, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, will take part in a fireside chat at 1:50 p.m. EST.
Investors, analysts, media and the public may listen via a live audio webcast at the company-provided weblink.
Merck (NYSE: MRK) is reorganizing its Human Health operating structure into two business units: Oncology and Specialty, Pharma & Infectious Diseases. Jannie Oosthuizen is appointed EVP and president, Oncology and MSD International; Brian Foard joins as EVP and president, Specialty, Pharma & Infectious Diseases effective March 2, 2026.
The company said it is conducting approximately 80 Phase 3 studies and expects >20 new growth drivers over the next several years, aiming to support multiple forthcoming launches and sustained commercial execution.
Merck (NYSE: MRK) reported positive Phase 3 SMART trial second RSV season data for ENFLONSIA (clesrovimab) in infants and children under 2 years at increased risk for severe RSV disease (presented Feb 19, 2026).
Safety in season 2 was generally consistent with season 1, serum concentrations matched pivotal CLEVER trial levels, and results support extrapolation of efficacy and regulatory submissions for an expanded indication through a second RSV season.
Merck (NYSE: MRK) and Mayo Clinic announced a research and development collaboration on February 18, 2026 to apply AI, advanced analytics and multimodal clinical data to support drug discovery and development.
The agreement gives Merck access to Mayo Clinic Platform data—de-identified clinical, genomic, imaging and molecular datasets—plus AI tools, registries and biorepositories to validate AI models and inform target identification in IBD, atopic dermatitis and multiple sclerosis.
Merck (NYSE: MRK) will present multiple genitourinary cancer data sets at the 2026 ASCO GU Cancers Symposium (Feb 26–28, 2026), including Phase 3 KEYNOTE-B15 showing significant improvements in event-free survival, overall survival and pathologic complete response for KEYTRUDA plus Padcev in muscle-invasive bladder cancer.
Additional featured results include LITESPARK-022 (adjuvant KEYTRUDA plus WELIREG) showing disease-free survival benefit and LITESPARK-011 (WELIREG plus LENVIMA) showing progression-free survival benefit in renal cell carcinoma.
Merck (NYSE: MRK) announced FDA approval of KEYTRUDA and KEYTRUDA QLEX plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ (CPS ≥1) platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma after one or two prior systemic regimens.
Approvals are based on Phase 3 KEYNOTE-B96: PFS HR 0.72 (28% risk reduction; p=0.0014), median PFS 8.3 vs 7.2 months; OS HR 0.76 (24% risk reduction; p=0.0053), median OS 18.2 vs 14.0 months. Safety signals include 54% serious adverse reactions and 3.9% fatal reactions.
Merck (NYSE: MRK) reported fourth-quarter 2025 worldwide sales of $16.4 billion (+5% / +4% ex-FX) and full-year sales of $65.0 billion (+1% / +2% ex-FX). Fourth-quarter GAAP EPS was $1.19 and non-GAAP EPS was $2.04; full-year GAAP EPS was $7.28 and non-GAAP EPS was $8.98. Key drivers included KEYTRUDA sales of $31.7 billion (+7%), strong Animal Health performance ($6.4 billion, +8%), and rising contributions from WINREVAIR and CAPVAXIVE. The company completed acquisitions of Verona Pharma and Cidara, reported positive Phase 3 readouts, and set 2026 sales outlook of $65.5–$67.0 billion with non-GAAP EPS guidance of $5.00–$5.15 (includes a one-time ~$3.65 per-share charge).
Merck (NYSE: MRK) announced the Board declared a quarterly cash dividend of $0.85 per share for the second quarter of 2026. Payment is scheduled for April 7, 2026 to shareholders of record at the close of business on March 16, 2026.
Moderna (NASDAQ:MRNA) and Merck (NYSE:MRK) reported median five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study showing that intismeran autogene plus KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510; 95% CI 0.294-0.887; one-sided nominal p=0.0075) versus KEYTRUDA alone in patients with resected high-risk stage III/IV melanoma.
The safety profile remained consistent with prior reports. Moderna and Merck plan further follow-up presentations and continue enrollment across eight Phase 2/3 studies, with the Phase 3 adjuvant melanoma trial fully enrolled.